US Department of Health & Human Services/Office of Biomedical Advanced Research and Development Authority (BARDA): Division of Research, Innovation & Ventures (DRIVe)- (Abstracts)

(Abstracts may be submitted at any time until the closing date)

AOI #22 ReBooT

BARDA is requesting abstract submissions for projects that evaluate existing therapeutics as medical countermeasures (MCM) against filoviruses. The candidates should be direct acting anti-virals or host directed products.

Broad spectrum antivirals with anticipated efficacy against multiple species or genera of viruses are preferred. Also, products that are orally available and have room temperature storage will be preferred. The ReBooT program will primarily focus on proposals for preclinical efficacy studies (i.e. efficacy in animal models of filovirus disease); such proposals should clearly delineate the proposed study design; laboratory partners, if required; outcome measures; and proposed threshold for study success, which could guide go/no go decisions for follow on funding.

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/reboot.html